Oncogene Inhibitors Market

Oncogene Inhibitors Market Size, Share & Trends Analysis Report

Oncogene Inhibitors Market 2020 By Genes (EGFR, HER , BRCA , Others), By Indication: (Breast Cancer, Ovarian Cancer , Lung Cancer , Pancreas Cancer , Others), By Treatment: (Platinum-Based Chemotherapy, PARP Inhibitors, Anti-HER Antibodies , EFGR Inhibitors , Others), By End-User: (Hospitals, Specialty Clinics , Others), By Distribution Channel: (Hospital Pharmacy , Retail Pharmacy , Others) Forecast To 2025

Report ID : BMRC 1146
Number of pages : 300
Published Date : Nov 2022
Category : Chemical And Materials
Delivery Timeline : 48 hrs

Increasing cases of cancer globally and introduction of newer technology are the major factors expected to drive the growth of Global Oncogene Inhibitors Market.

Scope of Global Oncogene Inhibitors Market Report-

Oncogene addiction is a phenomenon in which cancer could be tested by disabling single oncogene. Proto-oncogenes are main target of investigators because they may convert into oncogenes at any stage of life. Sequence level connection and identification of genetic factors are expected to shed more light on their working. It will let investigators to develop drugs capable of preventing oncogene activation and activity in the human body. Expansion of such therapeutics is a daunting task because human genome is quite big and contains variety of genes whose function has yet to be determined by investigators. Proto-oncogenes are genes that are primarily responsible to suppress cancerous cells or inhibit the cell differentiation and prevent from apoptosis. These genes are also involved in the cell division and are essential for maintaining healthy growth of the cells. The mutation in proto-oncogenes can leads to the development of cancer causing genes called oncogenes. The oncogenes inhibitors are a class of drugs that acts on the oncogenes such HER, EFGR or BRCA where drugs either antagonist the effect or inhibit the action of mutant genes and prevent them from uncontrollable growth. 

Global Oncogene Inhibitors market report is segmented based on genes, indication, treatment, end-users, distribution channel and regional & country level. Based upon genes, oncogene inhibitors market is classified into EGFR, HER, BRCA and others. Based upon indication, the market is classified into breast cancer, ovarian cancer, lung cancer, pancreas cancer and others. Based upon treatment, the market is classified into Platinum-based Chemotherapy, PARP Inhibitors, anti-HER Antibodies, EFGR Inhibitors and Others. Based upon end-users, oncogene inhibitors market is classified into hospitals, specialty clinics and others. Based upon distribution channel, oncogene inhibitors market is classified into hospital pharmacy, retail pharmacy and others.

The regions covered in this oncogene inhibitors market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, market of oncogene inhibitors is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

Oncogene Inhibitors Manufacturers:

Oncogene Inhibitors market report covers prominent players like,

  • straZeneca
  • Merck Sharp & Dohme Corp.
  • ArQule Inc.
  • Pfizer Inc.
  • AKRON, Inc.
  • Novartis AG
  • Galen Limited.
  • Pacira BioSciences, Inc
  • Johnson & Johnson Services, Inc
  • Fresenius Kabi AG
  • Spectrum Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited.
  • Teva Pharmaceutical Industries Ltd
  • Cipla Inc
  • Sun Pharmaceutical Industries Ltd
  • Shanghai Fosun Pharmaceutical(Group)Co. Ltd.
  • Ingenus
  • Others



Global Oncogene Inhibitors Market Dynamics–

Oncogene inhibitor market is a rapidly growing with numerous products at different stages of clinical pipeline and marketed products at different phases of industry life cycle. Medicinal firms are trying to provide efficient medical care to patients and create significant revenues by their sales. Huge patient base and superior technology are some important factors responsible for continuous growth of this market. According to National cancer Institute, in 2018, an estimated 1,735,350 new cases of cancer will be diagnosed in the United States and 609,640 people will die from the disease. Additionally, large number of clinical trial pipeline drugs and anticipated commercialization by various companies is one of the key driving factors during the forecast period. However, therapeutic for this gene are not available in market due to its complex protein structure may hinders oncogene inhibitors market. In spite of that, several oncogene inhibitor drugs are at the final stage of research and development and expected to create lucrative opportunity for the further growth of the market during the forecast period.

Global Oncogene Inhibitors Market Regional Analysis–

North America is expected to dominate the global oncogene inhibitors market with the potential rate in terms of revenue due to high prevalence of breast and melanoma cancer and increasing number of FDA approval drugs in this region. Melanoma is reported as the most common type of cancer worldwide with estimated, age-standardized incidence rates of 2.8–3.1 per 100,000 people. According to the American Cancer Society, about 96,480 new patients with melanomas would be diagnosed in the U.S. by the end of 2019. Out of these, about 39,260 would be women and 57,220 would be men. About 7,230 people are expected to die of melanoma. 

Europe is considered to hold bright growth prospects throughout the years due to launch of new drugs from the EMA and presence of refined healthcare management in this region.

Asia Pacific is anticipated to grow at a highest CAGR over forecast period due to rapidly evolving healthcare infrastructure and inclusion of research activities by medium as well as small scale players. Furthermore, the augmenting figure of patients within the region coupled with flexible regulatory guidelines are expected to promote the regional growth.

Key Benefits for Global Oncogene Inhibitors Market Report–

Global Market report covers in depth historical and forecast analysis.

Global Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market opportunities, Competitive Analysis, Regional and Country Level.

Global Market report helps to identify opportunities in market place.

Global Market report covers extensive analysis of emerging trends and competitive landscape.

Global Oncogene Inhibitors Market Segmentation:–

By Genes: EGFR, HER, BRCA, others

By Indication: Breast Cancer, Ovarian Cancer, Lung Cancer, Pancreas Cancer, Others

By Treatment: Platinum-based Chemotherapy, PARP Inhibitors, Anti-HER Antibodies, EFGR Inhibitors, Others

By End-User: Hospitals, Specialty Clinics, Others

By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Others

Regional & Country Analysis
North America, U.S., Mexico, Canada , Europe, UK, France, Germany, Italy , Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of Middle East and Africa

Vishal Sawant
Business Development
+91 8830 254 358

By Genes:

  • EGFR
  • HER
  • BRCA
  • others

By Indication:

  • Breast Cancer
  • Ovarian Cancer
  • Lung Cancer
  • Pancreas Cancer
  • Others

By Treatment:

  • Platinum-based Chemotherapy
  • PARP Inhibitors
  • Anti-HER Antibodies
  • EFGR Inhibitors
  • Others

By End-User:

  • Hospitals
  • Specialty Clinics
  • Others

By Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Others
Regions and Country

North America

  • U.S.
  • Canada


  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Sweden
  • Netherlands
  • Turkey
  • Switzerland
  • Belgium
  • Rest of Europe


  • South Korea
  • Japan
  • China
  • India
  • Australia
  • Philippines
  • Singapore
  • Malaysia
  • Thailand
  • Indonesia
  • Rest of APAC

Latin America

  • Mexico
  • Colombia
  • Brazil
  • Argentina
  • Peru
  • Rest of South America

Middle East and Africa

  • Saudi Arabia
  • UAE
  • Egypt
  • South Africa
  • Rest of MEA
Key Players
  • straZeneca
  • Merck Sharp & Dohme Corp.
  • ArQule Inc.
  • Pfizer Inc.
  • AKRON, Inc.
  • Novartis AG
  • Galen Limited.
  • Pacira BioSciences, Inc
  • Johnson & Johnson Services, Inc
  • Fresenius Kabi AG
  • Spectrum Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited.
  • Teva Pharmaceutical Industries Ltd
  • Cipla Inc
  • Sun Pharmaceutical Industries Ltd
  • Shanghai Fosun Pharmaceutical(Group)Co. Ltd.
  • Ingenus
  • Others


We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us



BrandEssence® Market Research and Consulting Pvt ltd.

124, City Road, London EC1V 2NX




1-888-853-7040 - U.S. (TOLL FREE)+44-1173181773 - U.K. OFFICE+91-7447409162 - INDIA OFFICE

© Copyright 2024-25 BrandEssence® Market Research and Consulting Pvt ltd. All Rights Reserved | Designed by BrandEssence®